a-comprehensive-procedure-to-evaluate-vivo-performance-cancer

A Comprehensive Procedure to Evaluate the <em>In Vivo</em> Performance of Cancer Nanomedicines

Inspired by the success of previous cancer nanomedicines in the clinic, researchers have generated a large number of novel formulations in the past ...

Memorial Sloan Kettering Cancer Center

Ataxia telangiectasia and Rad3-related (ATR) threonine serine kinase is one of the key elements in orchestrating the DNA damage response (DDR). As such, inhibition of ATR can amplify the effects of chemo- and radiation-therapy, and several ATR inhibitors (ATRi) have already undergone clinical testing in cancer. For more accurate patient selection, monitoring and staging, real-time in vivo imaging of ATR could be invaluable; the development of appropriate imaging agents has remained a major challenge.

Ahmad Sadique

Department of Radiology

Memorial Sloan Kettering Cancer Center

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Ahmad Sadique

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Radiology

Memorial Sloan Kettering Cancer Center

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Department of Radiology